Varsha Gandhi, PhD, on Ibrutinib

First International Summit on Interventional Pharmacoeconomics

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Peter Clark, MA, MD, FRCP: A Payer Perspective

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Dec

Today In Oncology

Varsha Gandhi, PhD, on Ibrutinib

Related Videos

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Peter Clark, MA, MD, FRCP: A Payer Perspective

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Nivolumab and Ipilimumab in Advanced dMMR/MSI-H Noncolorectal Cancers

FDA Grants Traditional Approval to Pirtobrutinib for CLL/SLL

Lung Cancer Deaths Prevented and Life-Years Gained From Lung Cancer Screening

AYA Cancers Survival for Metastatic Recurrence Worse Than De Novo Metastatic Disease

Survey Finds Global Embrace of Integrative Cancer Care